JGL, in partnership with the Center for proteomics, MEDRI, through research development activities in TPP “Health and Quality of Life”, smart specialisation strategies of the Republic of Croatia (S3), will develop a product that will affect the improvement of health and quality of life of people, relieve the health system and reduce losses caused by absenteeism. Rino SPREJ represents a step forward in the pharmaceutical industry based on the active substance and formulation of the effect, and its healing effect through innovative application will reduce symptoms and progression of colds caused by rhinovirus. At the end of the project, Rino SPREJ will be in TRL phase 6 and will enable JGL to increase sales and export revenues and new employment.